Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials

PLoS Neglected Tropical Diseases

Volumn 10, Issue 7, 2016, Pages

  Gailhardou, Sophia ^a   Skipetrova, Anna ^a   Dayan, Gustavo H ^a   Jezorwski, John ^a   Saville, Melanie ^a   Van der Vliet, Diane ^a   Wartel, T Anh ^b  

^a SANOFI PASTEUR   (France)

^b NONE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; LIVE VACCINE; PLACEBO; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANAPHYLAXIS; ARTHRALGIA; ARTICLE; ASTHENIA; BIOSAFETY; COUGHING; DENGUE; DIARRHEA; DIZZINESS; DRUG SAFETY; DRUG WITHDRAWAL; ETHNICITY; FEVER; FOLLOW UP; GASTROINTESTINAL DISEASE; HEADACHE; HOSPITALIZATION; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; LYMPHADENOPATHY; MALAISE; MULTICENTER STUDY (TOPIC); MYALGIA; NAUSEA; NECK PAIN; OROPHARYNX PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROFESSIONAL STANDARD; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RHINOPHARYNGITIS; RHINORRHEA; RISK ASSESSMENT; SEROTYPE; UPPER RESPIRATORY TRACT INFECTION; VIREMIA; VOMITING; ADOLESCENT; ADULT; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DENGUE VIRUS; FEMALE; GENETICS; IMMUNOLOGY; MALE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; DENGUE; DENGUE VACCINES; DENGUE VIRUS; FEMALE; HUMANS; MALE; MIDDLE AGED; VACCINATION; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 84980322304     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004821     Document Type: Article

References (50)

1. Simmons CP, Farrar JJ, Nguyen v V, Wills B, Dengue. N Engl J Med. 2012;366(15):1423–32. Epub 2012/04/13. doi: 10.1056/NEJMra111026522494122.
2. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–7. Epub 2013/04/09. doi: 10.1038/nature1206023563266; PubMed Central PMCID: PMCPMC3651993.
3. Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, et al. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis. 2012;6(8):e1760. Epub 2012/08/11. doi: 10.1371/journal.pntd.000176022880140; PubMed Central PMCID: PMCPMC3413714.
4. World Health Organization. Dengue and severe dengue. Fact sheet no. 117 2015 [20 November 2015]. Available from: http://www.who.int/mediacentre/factsheets/fs117/en/.
5. Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Human vaccines. 2006;2(2):60–7. Epub 2006/10/03. 17012873.
6. Capeding RZ, Luna IA, Bomasang E, Lupisan S, Lang J, Forrat R, et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine. 2011;29(22):3863–72. Epub 2011/04/12. doi: 10.1016/j.vaccine.2011.03.05721477675.
7. Dayan GH, Garbes P, Noriega F, Izoton de Sadovsky AD, Rodrigues PM, Giuberti C, et al. Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9–16 years in Brazil. Am J Trop Med Hyg. 2013;89(6):1058–65. doi: 10.4269/ajtmh.13-030424189367; PubMed Central PMCID: PMC3854882.
8. Dayan GH, Thakur M, Boaz M, Johnson C, Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA. Vaccine. 2013;31(44):5047–54. doi: 10.1016/j.vaccine.2013.08.08824021313.
9. Lanata CF, Andrade T, Gil AI, Terrones C, Valladolid O, Zambrano B, et al. Immunogenicity and safety of tetravalent dengue vaccine in 2–11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru. Vaccine. 2012;30(41):5935–41. Epub 2012/08/07. doi: 10.1016/j.vaccine.2012.07.04322863660.
10. Leo YS, Wilder-Smith A, Archuleta S, Shek LP, Chong CY, Leong HN, et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 y: Phase II randomized controlled trial in Singapore. Hum Vaccin Immunother. 2012;8(9):1259–71. Epub 2012/08/17. doi: 10.4161/hv.2122422894958; PubMed Central PMCID: PMCPmc3579907.
11. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J, A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis. 2010;201(3):370–7. Epub 2010/01/12. doi: 10.1086/64991620059357.
12. Poo J, Galan F, Forrat R, Zambrano B, Lang J, Dayan GH, Live-attenuated Tetravalent Dengue Vaccine in Dengue-naive Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity. Pediatr Infect Dis J. 2010;[Epub ahead of print]. Epub 2010/11/03. doi: 10.1097/INF.0b013e3181fe05af21042231.
13. Qiao M, Shaw D, Forrat R, Wartel-Tram A, Lang J, Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am J Trop Med Hyg. 2011;85(4):724–31. Epub 2011/10/07. doi: 10.4269/ajtmh.2011.10–043621976579; PubMed Central PMCID: PMCPmc3183784.
14. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012;380(9853):1559–67. Epub 2012/09/15. doi: 10.1016/S0140-6736(12)61428-722975340.
15. Tran NH, Luong CQ, Vu TQH, Forrat R, Lang J, Vu QD, et al. Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD-TDV) in healthy Vietnamese adults and children. J Vaccines Vaccin. 2012;3:162.
16. Villar LA, Rivera-Medina DM, Arredondo-Garcia JL, Boaz M, Starr-Spires L, Thakur M, et al. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9–16 year olds: a randomized, controlled, phase II trial in Latin America. Pediatr Infect Dis J. 2013;32(10):1102–9. doi: 10.1097/INF.0b013e31829b802224067553.
17. McArthur MA, Sztein MB, Edelman R, Dengue vaccines: recent developments, ongoing challenges and current candidates. Expert Rev Vaccines. 2013;12(8):933–53. Epub 2013/08/30. doi: 10.1586/14760584.2013.81541223984962; PubMed Central PMCID: PMC3773977.
18. Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J, From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine. 2011;29(42):7229–41. Epub 2011/07/13. doi: 10.1016/j.vaccine.2011.06.09421745521.
19. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384(9951):1358–65. Epub 2014/07/16. doi: 10.1016/s0140-6736(14)61060-625018116.
20. Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015;372(2):113–23. Epub 2014/11/05. doi: 10.1056/NEJMoa141103725365753.
21. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012;380(9853):1559–67. doi: 10.1016/S0140-6736(12)61428-722975340
22. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, et al. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. N Engl J Med. 2015;373(13):1195–206. Epub 2015/07/28. doi: 10.1056/NEJMoa150622326214039.
23. World Health OrganizationGuidelines for the clinical evaluation of dengue vaccines in endemic areas. Geneva: World Health Organization; 2008.
24. Bentsi-Enchill AD, Schmitz J, Edelman R, Durbin A, Roehrig JT, Smith PG, et al. Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation. Vaccine. 2013;31(23):2603–9. Epub 2013/04/11. doi: 10.1016/j.vaccine.2013.03.03823570986.
25. Poo J, Galan F, Forrat R, Zambrano B, Lang J, Dayan G, Live-attenuated Tetravalent Dengue Vaccine in Dengue-naive Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity. Pediatr Infect Dis J. 2011;30(1):e9–17. Epub 2010/11/03. doi: 10.1097/INF.0b013e3181fe05af21042231.
26. Dayan GH, Galan-Herrera JF, Forrat R, Zambrano B, Bouckenooghe A, Harenberg A, et al. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naive adults in Mexico. Hum Vaccin Immunother. 2014;10(10):2853–63. Epub 2014/12/09. doi: 10.4161/21645515.2014.97213125483647.
27. Harenberg A, Begue S, Mamessier A, Gimenez-Fourage S, Ching Seah C, Wei Liang A, et al. Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore. Hum Vaccin Immunother. 2013;9(11):5–4. doi: 10.4161/hv.25562
28. Dubey AP, Agarkhedkar S, Chhatwal J, Narayan A, Ganguly S, Wartel TA, et al. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: a randomized, observer-blind, placebo-controlled phase II trial. Hum Vaccin Immunother. 2015:0. Epub 2015/08/21. doi: 10.1080/21645515.2015.107659826291554.
29. Hss AS, Koh MT, Tan KK, Chan LG, Zhou L, Bouckenooghe A, et al. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2–11 years in Malaysia: a randomized, placebo-controlled, Phase III study. Vaccine. 2013;31(49):5814–21. doi: 10.1016/j.vaccine.2013.10.01324135573.
30. Torresi J, Heron LG, Qiao M, Marjason J, Chambonneau L, Bouckenooghe A, et al. Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: A randomised study. Vaccine. 2015;33(39):5127–34. Epub 2015/08/19. doi: 10.1016/j.vaccine.2015.08.00826279339.
31. Gershman MD, Staples JE, Bentsi-Enchill AD, Breugelmans JG, Brito GS, Camacho LA, et al. Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2012;30(33):5038–58. Epub 2012/05/09. doi: 10.1016/j.vaccine.2012.04.06722561144; PubMed Central PMCID: PMC3425393.
32. Staples JE, Gershman M, Fischer M, Centers for Disease C, PreventionYellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-7):1–27. Epub 2010/07/31. 20671663.
33. WHO Expert Committee on Biological StandardizationGuidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated). Annex 1 (Proposed replacement of WHO Technical Report Series, No. 932). Geneva: World Health Organization; 2011.
34. Capeding MR, Chua MN, Hadinegoro SR, Hussain II, Nallusamy R, Pitisuttithum P, et al. Dengue and other common causes of acute febrile illness in Asia: an active surveillance study in children. PLoS Negl Trop Dis. 2013;7(7):e2331. doi: 10.1371/journal.pntd.000233123936565; PubMed Central PMCID: PMC3723539.
35. Villar LA, Rojas DP, Besada-Lombana S, Sarti E, Epidemiological trends of dengue disease in Colombia (2000–2011): a systematic review. PLoS Negl Trop Dis. 2015;9(3):e0003499. Epub 2015/03/20. doi: 10.1371/journal.pntd.000349925790245; PubMed Central PMCID: PMCPmc4366106.
36. World Health OrganizationDengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd edition ed. Geneva: World Health Organization; 1997.
37. Cottin P, Niedrig M, Domingo C, Safety profile of the yellow fever vaccine Stamaril(R): a 17-year review. Expert Rev Vaccines. 2013;12(11):1351–68. doi: 10.1586/14760584.2013.83632024066727.
38. Monath TP, Seligman SJ, Robertson JS, Guy B, Hayes EB, Condit RC, et al. Live virus vaccines based on a yellow fever vaccine backbone: Standardized template with key considerations for a risk/benefit assessment. Vaccine. 2015;33(1):62–72. doi: http://dx.doi.org/10.1016/j.vaccine.2014.10.00425446819
39. Gritsun TS, Holmes EC, Gould EA, Analysis of flavivirus envelope proteins reveals variable domains that reflect their antigenicity and may determine their pathogenesis. Virus Res. 1995;35(3):307–21. Epub 1995/03/01. 7785318.
40. Guzman MG, Kouri G, Dengue: an update. Lancet Infect Dis. 2002;2(1):33–42. Epub 2002/03/15. 11892494.
41. Guzman MG, Alvarez M, Halstead SB, Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol. 2013;158(7):1445–59. Epub 2013/03/09. doi: 10.1007/s00705-013-1645-323471635.
42. Rothman AL, Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nature reviews Immunology. 2011;11(8):532–43. Epub 2011/07/16. doi: 10.1038/nri301421760609.
43. Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E, et al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS pathogens. 2010;6(2):e1000790. Epub 2010/02/20. doi: 10.1371/journal.ppat.100079020168989; PubMed Central PMCID: PMCPmc2820409.
44. Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ, Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci USA. 2007;104(22):9422–7. Epub 2007/05/23. doi: 10.1073/pnas.070349810417517625; PubMed Central PMCID: PMCPmc1868655.
45. Guzman MG, Vazquez S, The complexity of antibody-dependent enhancement of dengue virus infection. Viruses. 2010;2(12):2649–62. Epub 2011/10/14. doi: 10.3390/v212264921994635; PubMed Central PMCID: PMCPmc3185591.
46. Zellweger RM, Prestwood TR, Shresta S, Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe. 2010;7(2):128–39. Epub 2010/02/16. doi: 10.1016/j.chom.2010.01.00420153282; PubMed Central PMCID: PMCPmc2824513.
47. Guy B, Briand O, Lang J, Saville M, Jackson N, Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward. Vaccine. 2015;33(50):7100–11. Epub 2015/10/18. doi: 10.1016/j.vaccine.2015.09.10826475445.
48. Guy B, Jackson N, Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nature reviews Microbiology. 2016;14(1):45–54. Epub 2015/12/08. doi: 10.1038/nrmicro.2015.226639777.
49. Guy B, Moser J, Byers A, Kachurin A, Harenberg A, Boudet F, et al. Immunological investigations to understand the outcome of the phase III efficacy studies of the Sanofi Pasteur dengue vaccine (Abstract no. 553). American Society of Tropical Medicine and Hygiene—64th Annual Meeting; 2015 October 25–29; Philadelphia, PA.
50. World Health Organisation. Dengue vaccine research 2016 [30 April 2016]. Available from: http://www.who.int/immunization/research/development/dengue_vaccines/en/.